These results are in accordance with a previous report, indicating that successful treatment of pancreatic cancer may require compound inhibition of at least 4 distinct signaling cascades, including those driven by KRAS, EGFR, PI3K and STAT3 [11]. This evidence concerns the gene KRAS and pancreatic neoplasm.